• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

包含查尔森合并症指数评分的综合评分系统在间质性肺疾病患者中的临床应用价值。

Clinical utility of a composite scoring system including Charlson Comorbidity Index score in patients with interstitial lung disease.

作者信息

Yagyu Hiroyuki, Murohashi Kota, Hara Yu, Saigusa Yusuke, Aoki Ayako, Kobayashi Nobuaki, Kaneko Takeshi

机构信息

Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

出版信息

J Thorac Dis. 2020 Oct;12(10):5774-5782. doi: 10.21037/jtd-20-1302.

DOI:10.21037/jtd-20-1302
PMID:33209409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7656418/
Abstract

BACKGROUND

Prognostic factors have yet to be established for patients with interstitial lung disease (ILD). We aimed to clarify whether the Charlson Comorbidity Index score (CCIS) could help predict disease prognosis in patients with ILD.

METHODS

Among ILD patients treated between April 2013 and April 2017, we retrospectively assessed the relationship between baseline clinical parameters including age, sex, CCIS, ILD diagnosis, pulmonary function test results, and 3-year ILD-related events including cause-specific death and first acute exacerbation (AE).

RESULTS

We assessed 180 patients (mean age, 74 years), all of whom underwent pulmonary function testing including percentage predicted diffusion capacity for carbon monoxide (%D). Underlying pathologies included idiopathic pulmonary fibrosis (IPF) in 57 cases, idiopathic nonspecific interstitial pneumonia (iNSIP) and collagen vascular disease-related interstitial pneumonia in 117 cases, and chronic hypersensitivity pneumonia (CHP) in 6 cases. A composite scoring system comprising IPF diagnosis, CCIS, and %D provided a favorable C-index (0.825) for predicting 3-year ILD-related events. The nomogram for 3-year prognosis revealed the largest contributions from CCIS, %D and IPF diagnosis.

CONCLUSIONS

This composite scoring system accounting for IPF diagnosis, CCIS, and %D could provide a useful tool for predicting prognosis in relatively mild ILD patients tolerated to pulmonary diffusion capacity testing.

摘要

背景

间质性肺疾病（ILD）患者的预后因素尚未明确。我们旨在明确查尔森合并症指数评分（CCIS）是否有助于预测ILD患者的疾病预后。

方法

在2013年4月至2017年4月接受治疗的ILD患者中，我们回顾性评估了包括年龄、性别、CCIS、ILD诊断、肺功能测试结果等基线临床参数与3年ILD相关事件（包括特定病因死亡和首次急性加重（AE））之间的关系。

结果

我们评估了180例患者（平均年龄74岁），所有患者均接受了肺功能测试，包括一氧化碳预测弥散百分比（%D）。潜在病理包括57例特发性肺纤维化（IPF）、117例特发性非特异性间质性肺炎（iNSIP）和胶原血管病相关间质性肺炎以及6例慢性过敏性肺炎（CHP）。一个由IPF诊断、CCIS和%D组成的综合评分系统对预测3年ILD相关事件具有良好的C指数（0.825）。3年预后的列线图显示CCIS、%D和IPF诊断的贡献最大。

结论

这个考虑了IPF诊断、CCIS和%D的综合评分系统可为相对轻度且能耐受肺弥散功能测试的ILD患者提供一个有用的预后预测工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/b5c845750587/jtd-12-10-5774-fS.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/5bad5d2acf45/jtd-12-10-5774-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/30a69e0362c2/jtd-12-10-5774-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/1cb8c9e9db5b/jtd-12-10-5774-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/9a67d26029b5/jtd-12-10-5774-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/e4e85399ff11/jtd-12-10-5774-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/823a88c35920/jtd-12-10-5774-fS.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/b5c845750587/jtd-12-10-5774-fS.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/5bad5d2acf45/jtd-12-10-5774-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/30a69e0362c2/jtd-12-10-5774-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/1cb8c9e9db5b/jtd-12-10-5774-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/9a67d26029b5/jtd-12-10-5774-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/e4e85399ff11/jtd-12-10-5774-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/823a88c35920/jtd-12-10-5774-fS.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c44/7656418/b5c845750587/jtd-12-10-5774-fS.2.jpg

相似文献

1
Clinical utility of a composite scoring system including Charlson Comorbidity Index score in patients with interstitial lung disease.包含查尔森合并症指数评分的综合评分系统在间质性肺疾病患者中的临床应用价值。
J Thorac Dis. 2020 Oct;12(10):5774-5782. doi: 10.21037/jtd-20-1302.
2
ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease.ILD-GAP 联合 Charlson 共病指数评分（ILD-GAPC）作为间质性肺疾病患者的预后预测模型。
Can Respir J. 2023 Feb 8;2023:5088207. doi: 10.1155/2023/5088207. eCollection 2023.
3
ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases.ILD-GAP 联合单核细胞比率可能比 ILD-GAP 更能预测间质性肺疾病患者的预后。
BMC Pulm Med. 2024 Jan 5;24(1):16. doi: 10.1186/s12890-023-02833-6.
4
Clinical features of acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: Comparison with idiopathic pulmonary fibrosis.类风湿关节炎相关间质性肺疾病急性加重的临床特征：与特发性肺纤维化的比较。
Respir Med. 2022 Aug-Sep;200:106898. doi: 10.1016/j.rmed.2022.106898. Epub 2022 Jun 4.
5
The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study.特发性肺纤维化患者在接受抗纤维化治疗时合并症的临床影响：一项多中心回顾性观察研究。
PLoS One. 2023 Sep 19;18(9):e0291489. doi: 10.1371/journal.pone.0291489. eCollection 2023.
6
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验：吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
7
Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.特发性肺纤维化以外的间质性肺疾病患者急性加重后的预后。
Clin Respir J. 2021 Mar;15(3):336-344. doi: 10.1111/crj.13304. Epub 2020 Dec 10.
8
Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.与自身抗体相关的特发性间质性肺炎：一项为期1年的大型病例系列研究
Chest. 2017 Jul;152(1):103-112. doi: 10.1016/j.chest.2017.03.004. Epub 2017 Mar 12.
9
Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.结缔组织病相关性间质性肺炎与慢性纤维化特发性间质性肺炎的临床过程和死亡率比较。
Kaohsiung J Med Sci. 2019 Jun;35(6):365-372. doi: 10.1002/kjm2.12066. Epub 2019 Mar 26.
10
Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?风险预测模型对评估类风湿关节炎相关间质性肺疾病患者的生存率有用吗？
BMC Pulm Med. 2017 Jan 13;17(1):16. doi: 10.1186/s12890-016-0358-2.

引用本文的文献

1
The DSC Index: A new prognostic tool for evaluating functional status in interstitial lung disease.DSC指数：一种评估间质性肺疾病功能状态的新预后工具。
Sarcoidosis Vasc Diffuse Lung Dis. 2025 Mar 18;42(1):13949. doi: 10.36141/svdld.v42i1.13949.
2
Evaluation of comorbidity burden on disease progression and mortality in patients with interstitial pneumonia with autoimmune features: A retrospective cohort study.自身免疫特征性间质性肺炎患者共病负担对疾病进展和死亡率的评估：一项回顾性队列研究
PLoS One. 2025 Feb 4;20(2):e0316762. doi: 10.1371/journal.pone.0316762. eCollection 2025.
3
Relationship of oral bacterial number with medical hospitalization costs in analysis of Diagnosis Procedure Combination database from single institution in Japan.

本文引用的文献

1
Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.加拿大肺纤维化注册研究中的基线特征和合并症。
BMC Pulm Med. 2019 Nov 27;19(1):223. doi: 10.1186/s12890-019-0986-4.
2
Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia.查尔森合并症指数作为急性或亚急性特发性间质性肺炎及胶原血管病相关间质性肺炎急性加重患者预后参数的临床意义。
J Thorac Dis. 2019 Jun;11(6):2448-2457. doi: 10.21037/jtd.2019.05.46.
3
日本单机构诊断程序组合数据库分析中口腔细菌数量与医疗住院费用的关系。
Sci Rep. 2024 May 15;14(1):11114. doi: 10.1038/s41598-024-60733-z.
4
The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan's National Health Insurance Research Database.秋水仙碱对免疫介导的炎症性疾病患者癌症风险的影响：基于台湾全民健康保险研究数据库的时间依赖性研究。
Eur J Med Res. 2024 Apr 22;29(1):245. doi: 10.1186/s40001-024-01836-1.
5
The Impact of Chronic Comorbidities on Outcomes in Acute Exacerbations of Idiopathic Pulmonary Fibrosis.慢性合并症对特发性肺纤维化急性加重期预后的影响
Life (Basel). 2024 Jan 21;14(1):156. doi: 10.3390/life14010156.
6
ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases.ILD-GAP 联合单核细胞比率可能比 ILD-GAP 更能预测间质性肺疾病患者的预后。
BMC Pulm Med. 2024 Jan 5;24(1):16. doi: 10.1186/s12890-023-02833-6.
7
＜Editors' Choice＞ Comparison of clinical features between patients with acute exacerbation of idiopathic interstitial pneumonia and collagen vascular disease-associated interstitial pneumonia.＜编辑推荐＞ 特发性间质性肺炎急性加重患者与胶原血管病相关间质性肺炎患者临床特征的比较
Nagoya J Med Sci. 2023 Aug;85(3):602-611. doi: 10.18999/nagjms.85.3.602.
8
The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study.特发性肺纤维化患者在接受抗纤维化治疗时合并症的临床影响：一项多中心回顾性观察研究。
PLoS One. 2023 Sep 19;18(9):e0291489. doi: 10.1371/journal.pone.0291489. eCollection 2023.
9
Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease.预测纤维化间质性肺疾病新发运动性和静息性低氧血症。
Ann Am Thorac Soc. 2023 Dec;20(12):1726-1734. doi: 10.1513/AnnalsATS.202303-208OC.
10
ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease.ILD-GAP 联合 Charlson 共病指数评分（ILD-GAPC）作为间质性肺疾病患者的预后预测模型。
Can Respir J. 2023 Feb 8;2023:5088207. doi: 10.1155/2023/5088207. eCollection 2023.
Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
结缔组织病相关性间质性肺炎与慢性纤维化特发性间质性肺炎的临床过程和死亡率比较。
Kaohsiung J Med Sci. 2019 Jun;35(6):365-372. doi: 10.1002/kjm2.12066. Epub 2019 Mar 26.
4
The Charlson Comorbidity Index as an Independent Prognostic Factor in Older Colorectal Cancer Patients.查尔森合并症指数作为老年结直肠癌患者的独立预后因素
Indian J Surg. 2018 Feb;80(1):54-60. doi: 10.1007/s12262-016-1544-4. Epub 2016 Aug 24.
5
Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer.IIIb 期-IV 期非小细胞肺癌患者 Charlson 合并症指数评分与结局的相关性。
BMC Pulm Med. 2017 Aug 15;17(1):112. doi: 10.1186/s12890-017-0452-0.
6
Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.使用GAP评分预测特发性肺纤维化患者的生存率：一项全国性队列研究。
Respir Res. 2016 Oct 18;17(1):131. doi: 10.1186/s12931-016-0454-0.
7
Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis.特发性肺纤维化急性加重的危险因素。
Respir Res. 2016 Jul 11;17(1):79. doi: 10.1186/s12931-016-0400-1.
8
Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.合并症对特发性肺纤维化患者死亡率的影响
PLoS One. 2016 Mar 29;11(3):e0151425. doi: 10.1371/journal.pone.0151425. eCollection 2016.
9
Predicting survival across chronic interstitial lung disease: the ILD-GAP model.预测慢性间质性肺病的生存情况：ILD-GAP 模型。
Chest. 2014 Apr;145(4):723-728. doi: 10.1378/chest.13-1474.
10
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.美国胸科学会/欧洲呼吸学会官方声明：特发性间质性肺炎的国际多学科分类的更新。
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST.